Alnylam Pharmaceuticals | ALNY - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
Acadia Pharmaceuticals USD 270.12M 2.55M 2026-06
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
Alnylam Pharmaceuticals USD 1.06B 160.97M 2026-06
Amgen USD 11.69B 6.9B 2026-06
Arrowhead Research USD 245.35M 30.35M 2026-06
BioCryst Pharmaceuticals USD 119.78M 673.63M 2026-06
BioMarin Pharmaceutical USD 6.32B 5.69B 2026-06
Incyte USD 973.64M 4.65B 2026-06
Ionis Pharmaceuticals USD 370.24M 6.24M 2026-06
Moderna USD 960M 817M 2026-06
Neurocrine Biosciences USD 739.1M 139.2M 2026-06
Novartis USD 9.29B 507M 2026-03
PTC Therapeutics USD 226.66M 19.64M 2026-03
Regeneron Pharmaceuticals USD 31.71B 287.8M 2026-06
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Sanofi EUR 8.98B 1.73B 2026-03
Sarepta Therapeutics USD 387.96M 15.59M 2026-06
Takeda JPY 1.02T 89.68B 2026-06
Tectonic Therapeutic USD 27.3M 5.78M 2026-03
Ultragenyx Pharmaceutical USD 289M 16M 2026-06
Vertex Pharmaceuticals USD 2.07B 217.1M 2026-06
Xencor USD 87.82M 5.44M 2026-06